康泰医学系统（秦皇岛）股份有限公司 独立董事 2024 年度述职报告 各位董事、各位股东： 本人作为康泰医学系统（秦皇岛）股份有限公司（以下简称"康泰医学"或 "公司"）的独立董事，严格按照《中华人民共和国公司法》《上市公司治理准 则》和《上市公司独立董事管理办法》等法律法规以及《康泰医学系统（秦皇岛） 股份有限公司章程》（以下简称"《公司章程》"）的规定，认真履行独立董事 职责，认真、勤勉地行使公司所赋予独立董事的权利，充分发挥独立董事作用， 切实维护了公司整体利益及全体股东尤其是中小股东合法权益。现将本人 2024 年度履职情况总结如下： 一、独立董事的基本情况 李华，独立董事，女，中国国籍，无境外永久居留权，1971 年 11 月出生， 汉族，本科学历，中国注册会计师、中国注册税务师、造价工程师、高级会计师。 历任秦皇岛市财政局人事教育科科员、秦皇岛会计师事务所注册会计师、秦皇岛 嘉华会计师事务所所长助理；2001 年 12 月至 2010 年 11 月在秦皇岛正源会计师 事务所任部门经理、所长助理；2010 年 12 月至今在秦皇岛至诚会计师事务所任 副所长；2022 年 5 月至今，任康泰医学系统（ ...

康泰医学系统（秦皇岛）股份有限公司 会计师事务所选聘制度 第一章 总 则 第一条 为规范康泰医学系统（秦皇岛）股份有限公司（以下简称"公司"） 选聘（含续聘、改聘）会计师事务所的行为，提高财务信息质量，切实维护公司 和股东利益，根据《中华人民共和国公司法》、《国有企业、上市公司选聘会计 师事务所管理办法》等相关的法律法规和《康泰医学系统（秦皇岛）股份有限公 司章程》（以下简称"《公司章程》"）的有关规定，结合公司实际情况，特制 定本制度。 第二条 本制度所称选聘会计师事务所，是指公司根据相关法律法规的要求， 聘任会计师事务所对财务会计报告发表审计意见、出具审计报告的行为。公司聘 任会计师事务所从事除财务会计报告审计之外的其他法定审计业务的，可以参照 本制度执行。 第三条 公司聘用或解聘会计师事务所应当由董事会审计委员会全体成员过 半数审议同意后，提交董事会审议，并由股东会决定。董事会不得在股东会决定 前委任会计师事务所。公司不得在董事会、股东会审议前聘请会计师事务所开展 审计业务。 第四条 公司保证向聘用的会计师事务所提供真实、完整的会计凭证、会计 账簿、财务会计报告及其他会计资料，不得拒绝、隐匿、谎报。 公 ...

第一条 为规范康泰医学系统（秦皇岛）股份有限公司（以下简称"公司"） 对外担保行为，有效控制担保风险，保障公司资产安全，根据《中华人民共和国 公司法》和《康泰医学系统（秦皇岛）股份有限公司章程》（以下简称"《公司 章程》"）的有关规定，结合公司实际情况，制定本办法。 第二条 本办法所称对外担保是指公司以第三人的身份为债务人对于债权人 所负的债务提供担保，当债务人不履行债务时，由公司按照约定履行债务或者承 担责任的行为。担保形式包括保证、抵押及质押。 康泰医学系统（秦皇岛）股份有限公司 对外担保管理办法 第一章 总则 对外担保包括公司对控股子公司提供的担保。 公司以自有资产为自身债务提供抵押、质押或其他形式的担保，不属于上述 对外担保，参照相关法律法规执行。 第三条 公司股东会和董事会是对外担保的决策机构。未经公司董事会或股 东会批准，公司不得对外提供担保。 第四条 本办法适用于公司、公司的全资及控股子公司（以下合称"控股子 公司"）。 公司控股子公司为公司合并报表范围内的法人或其他组织提供担保的，公司 应当在控股子公司履行审议程序后及时披露。 公司控股子公司为前款规定主体以外的其他主体提供担保的，视同公司提供 ...

康泰医学系统（秦皇岛）股份有限公司 董事会薪酬与考核委员会工作细则 第一章 总则 第一条 为进一步建立健全康泰医学系统（秦皇岛）股份有限公司（以下简 称"公司"）董事（包括非独立董事）及高级管理人员的考核和薪酬管理制度， 完善公司治理结构，根据《中华人民共和国公司法》《康泰医学系统（秦皇岛） 股份有限公司章程》（以下简称"公司章程"）等规定，公司特设立董事会薪酬 与考核委员会，并制定本工作细则。 第二条 薪酬与考核委员会是董事会按照股东会决议设立的专门工作机构， 主要负责制定、审查公司董事、高级管理人员的薪酬政策与方案，负责制定公司 董事及高级管理人员的考核标准并进行考核，对董事会负责。 第二章 人员组成 第三条 薪酬与考核委员会由三名董事组成，其中独立董事两名。 第四条 薪酬与考核委员会委员由董事长、二分之一以上独立董事或者全体 董事的三分之一提名，并由董事会选举产生。 第五条 薪酬与考核委员会设主任委员（召集人）一名，由独立董事担任， 负责主持委员会的工作。主任委员由董事会在委员中任命。 第六条 薪酬与考核委员会委员任期与董事任期一致，委员任期届满，连选 可以连任。期间如有委员不再担任公司董事职务，自动失 ...

康泰医学系统（秦皇岛）股份有限公司 章程 二〇二五年四月 | 第一章 总则 2 | | | | --- | --- | --- | | 第二章 经营宗旨和范围 3 | | | | 第三章 股份 4 | | | | 股份发行 | 第一节 | 4 | | 股份增减和回购 5 | 第二节 | | | 股份转让 | 第三节 | 7 | | 第四章 股东和股东会 7 | | | | 股东 | 第一节 | 7 | | 控股股东、实际控制人 10 | 第二节 | | | 股东会的一般规定 11 | 第三节 | | | 股东会的召集 15 | 第四节 | | | 股东会的提案与通知 17 | 第五节 | | | 股东会的召开 18 | 第六节 | | | 股东会的表决和决议 21 | 第七节 | | | 第五章 董事会 26 | | | | 董事 | 第一节 | 26 | | 董事会 | 第二节 | 30 | | 独立董事 | 第三节 | 35 | | 董事会专门委员会 39 | 第四节 | | | 第六章 高级管理人员 41 | | | | 第七章 财务会计制度、利润分配和审计 43 | | | | 财务会计制度 43 | ...

康泰医学系统（秦皇岛）股份有限公司 独立董事 2024 年度述职报告 各位董事、各位股东： 本人作为康泰医学系统（秦皇岛）股份有限公司（以下简称"康泰医学"或 "公司"）的独立董事，严格按照《中华人民共和国公司法》《上市公司治理准 则》和《上市公司独立董事管理办法》等法律法规以及《康泰医学系统（秦皇岛） 股份有限公司章程》（以下简称"《公司章程》"）的规定，认真履行独立董事 职责，认真、勤勉地行使公司所赋予独立董事的权利，充分发挥独立董事作用， 切实维护了公司整体利益及全体股东尤其是中小股东合法权益。现将本人 2024 年度履职情况总结如下： 一、独立董事的基本情况 杨长东，独立董事，男，中国国籍，无境外永久居留权，1967 年 1 月出生， 汉族，本科学历，中共党员，耳鼻咽喉头颈外科主任医师。2018 年 11 月至今任 河北省秦皇岛市第一医院甲状腺头颈颌面外科主任，耳鼻咽喉头颈外科副主任； 2023 年 5 月至今，任康泰医学系统（秦皇岛）股份有限公司独立董事。报告期 内，本人任职符合《上市公司独立董事管理办法》第六条规定的独立性要求，不 存在影响独立性的情况。 二、独立董事年度履职概况 2024 年度， ...

Financial Performance - The company achieved operating revenue of CNY 479.81 million, a year-on-year decrease of 35.76%[5] - The net profit attributable to shareholders was CNY -77.90 million, a year-on-year decline of 147.00%[5] - The significant decline in performance was primarily due to decreased main business revenue, large inventory impairment provisions, and consistently high R&D expenses[5] - The company recognized an inventory impairment provision of CNY 109.45 million, significantly impacting net profit[5] - The net profit attributable to shareholders for 2024 was -¥77,902,564.68, representing a decline of 147.00% from ¥165,765,985.80 in 2023[22] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥95,079,251.37 in 2024, down 163.49% from ¥149,747,034.60 in 2023[22] - The net cash flow from operating activities for 2024 was ¥62,342,578.82, a decrease of 65.56% compared to ¥181,014,720.43 in 2023[22] - The total assets at the end of 2024 were ¥2,725,517,187.03, down 15.14% from ¥3,211,946,652.17 at the end of 2023[22] - The net assets attributable to shareholders at the end of 2024 were ¥1,857,415,749.92, a decrease of 9.16% from ¥2,044,796,689.28 at the end of 2023[22] - The company experienced a negative net profit for the last three accounting years, indicating uncertainty in its ability to continue as a going concern[22] Research and Development - R&D expenses for the year were CNY 105.16 million, remaining stable compared to the previous year despite overall operational pressure[5] - The company plans to maintain a high level of R&D investment to support long-term strategic goals[6] - The company is actively increasing R&D investment to improve product technology and added value, aiming to close the gap with international standards[37] - The company has established a robust R&D mechanism, supported by a diverse team of high-level talents across various fields, leading to a total of 473 valid patents and 252 software copyrights[80] - The company is developing a high-quality ECG acquisition and printing technology to meet diverse market needs and enhance performance[130] - The company is working on a respiratory-triggered nebulizer technology that can be easily activated with minimal breath, aiming to enhance its nebulization product line[131] - The company is focusing on AI technology applications in health monitoring, enhancing the portability and accuracy of monitoring devices[195] Product Development and Innovation - The company has developed and launched 12 new products, including dental zirconia blocks and blood glucose monitoring devices, expanding its product range[92] - The company has introduced a wearable blood oxygen detection device that supports data storage and upload, enhancing patient monitoring capabilities[48] - The company has developed advanced ultrasound diagnostic systems that utilize digital beamforming technology for high-quality imaging[41] - The company is developing a color Doppler ultrasound diagnostic system, which is currently in the technical review stage for EU CE certification[134] - The company is set to launch a new blood cell analyzer, aimed at enhancing market competitiveness[130] - The company is developing a new oxygen supply system with a fivefold equivalent oxygen supply capacity compared to traditional oxygen machines, enhancing product variety and market competitiveness[131] - The company is expanding its product line to include various blood pressure and respiratory monitoring devices, enhancing its market presence in the healthcare sector[49] Market Presence and Strategy - The company has expanded its global market presence, selling products to over 140 countries and regions, enhancing its brand recognition internationally[38] - The company aims to enhance operational efficiency and expand its customer base through continuous innovation and cost reduction measures[6] - The company is actively pursuing new product development in areas such as medical endoscopes and in vitro diagnostics, enhancing its technological capabilities[91] - The company plans to expand its market presence in Europe, targeting a 30% increase in sales in that region over the next two years[149] - The company aims to optimize product market layout and increase market penetration, particularly targeting high-end hospitals and emerging markets with competitive pricing strategies[198] Financial Management and Investment - The company invested CNY 47.27 million in convertible bond fundraising projects this year, with a cumulative investment of CNY 92.53 million and a remaining balance of CNY 650.86 million[101] - The total investment amount for the reporting period was 5,474,764,736.37 RMB, representing a 162.56% increase from the previous year's investment of 890,735,599.29 RMB[171] - The company has cumulatively invested 48,165.78 million RMB in fundraising projects, with 4,726.51 million RMB invested in the current year[175] - The company has identified new product development areas, including instant testing (POCT) strips and analysis testing products, to expand its product range and market presence[180] Regulatory Compliance and Certifications - The company has obtained 66 medical device registrations, including 1 Class III, 60 Class II, and 5 Class I registrations, with 52 market access licenses globally[4] - The company has received domestic registration and EU CE certification for multiple products in the respiratory and infusion fields, achieving good sales performance[94] - The company has obtained registration certificates for 19 medical devices, with the latest being the fetal heart rate monitor registered on April 2, 2023, valid until April 27, 2028[143] Operational Efficiency - The company has implemented a lean production model to enhance cost efficiency and product quality, optimizing supply chain management to reduce raw material costs[101] - The company’s governance structure has been enhanced, improving decision-making and risk management capabilities[116] - The company is committed to improving logistics and delivery systems to shorten delivery times and enhance market competitiveness[198] Customer Engagement and Service - The company focuses on high-quality customer service, providing comprehensive pre-sale, in-sale, and post-sale support[88] - The company will provide comprehensive pre-sale, in-sale, and after-sale services to strengthen customer loyalty and support sustainable development[200]

Financial Performance - The company's revenue for Q1 2025 was ¥111,844,411.72, representing a 12.77% increase compared to ¥99,175,164.46 in the same period last year[5]. - Net profit attributable to shareholders reached ¥16,435,767.78, a significant increase of 277.67% from ¥4,351,935.11 in the previous year[5]. - The basic earnings per share rose to ¥0.0409, up 278.70% from ¥0.0108 in the previous year[5]. - Total operating revenue for the current period reached ¥111,844,411.72, an increase of 12.7% compared to ¥99,175,164.46 in the previous period[17]. - Net profit for the current period was ¥16,435,767.78, a significant increase of 276.5% compared to ¥4,351,935.11 in the previous period[18]. - The company reported a total comprehensive income of ¥16,574,365.03, compared to ¥4,216,671.58 in the previous period, marking a substantial increase[19]. Cash Flow - The net cash flow from operating activities was ¥29,947,843.54, a remarkable increase of 5,580.54% compared to a negative cash flow of ¥546,439.44 in the same period last year[5]. - Operating cash flow generated was ¥29,947,843.54, a turnaround from a negative cash flow of ¥546,439.44 in the previous period[21]. - Net cash flow from investment activities was -19,016,952.58, compared to 280,116,061.20 in the previous period[22]. - Cash inflow from financing activities totaled 53,446,896.37, down from 143,160,301.37 year-over-year[22]. - Cash outflow for financing activities was 963,194.31, significantly lower than 142,278,214.92 in the previous period[22]. - The net increase in cash and cash equivalents was 63,074,699.29, compared to 282,350,673.49 previously[22]. - The ending balance of cash and cash equivalents was 747,382,470.77, slightly down from 749,573,920.22[22]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,787,405,167.13, reflecting a 2.27% increase from ¥2,725,517,187.03 at the end of the previous year[5]. - Total current assets increased to ¥2,144,746,579.76 from ¥1,921,219,260.88, representing a growth of approximately 11.7%[15]. - Total liabilities increased to ¥913,415,052.18, compared to ¥868,101,437.11 in the previous period, reflecting a growth of 5.2%[16]. - Non-current assets totaled ¥642,658,587.37, down from ¥804,297,926.15, indicating a decrease of approximately 20.1%[15]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 31,459[11]. - The largest shareholder, Hu Kun, holds 46.84% of shares, totaling 188,189,252 shares[11]. - The company's equity attributable to shareholders increased to ¥1,873,990,114.95, a 0.89% rise from ¥1,857,415,749.92 at the end of the previous year[5]. - Total equity attributable to shareholders reached ¥1,873,990,114.95, up from ¥1,857,415,749.92, indicating a growth of 0.9%[16]. Other Financial Metrics - The company reported a significant increase in prepayments, which rose by 54.9% to ¥9,570,191.80 due to increased procurement payments[9]. - The company experienced a 285.88% increase in taxes payable, amounting to ¥5,899,560.77, attributed to higher sales and profit levels[9]. - Research and development expenses were ¥22,572,126.74, down 16.8% from ¥27,140,047.87 in the previous period[18]. - Total operating costs decreased to ¥93,516,783.56, down 8.1% from ¥102,176,199.13 in the previous period[17]. - Trading financial assets rose significantly to ¥672,307,189.11 from ¥171,588,083.19, indicating a growth of approximately 292.5%[13]. - Short-term borrowings increased to ¥91,436,896.37 from ¥60,000,000.00, reflecting a rise of approximately 52.4%[15]. - Accounts receivable decreased slightly to ¥45,683,043.03 from ¥45,998,781.84[15]. - Inventory decreased to ¥265,882,645.56 from ¥272,322,956.49, showing a decline of approximately 2.4%[15]. - Non-recurring gains and losses totaled ¥2,666,103.66, primarily driven by government subsidies and fair value changes of financial assets[6]. Audit Status - The company has not yet audited its first-quarter report for 2025[23].

证券代码：300869 证券简称：康泰医学 公告编号：2025-016 债券代码：123151 债券简称：康医转债 康泰医学系统（秦皇岛）股份有限公司 关于获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 康泰医学系统（秦皇岛）股份有限公司（以下简称"公司"）于近日取得了由 河北省药品监督管理局颁发的《中华人民共和国医疗器械注册证》，具体情况如下： 一、医疗器械注册证内容 注册人名称：康泰医学系统（秦皇岛）股份有限公司 产品名称：麻醉视频喉镜 型号、规格：CMS-GS1、CMS-GS2 适用范围：供临床挑起患者会厌部暴露声门，指引医护人员准确进行气道插管 供麻醉或急救用，也可用于口腔内诊查，治疗。 注册证编号：冀械注准 20252080109 批准日期：2025 年 04 月 16 日 生效日期：2025 年 04 月 16 日 有效期至：2030 年 04 月 15 日 二、对公司的影响及风险提示 以上产品医疗器械注册证的取得，有利于丰富公司产品线，进一步提高公司的 核心竞争力，对公司发展具有正面影响。上述产品后期实际销售情况取决于未 ...

4月16日，康泰医学今日收盘12.71元，下跌2.61%，最新市净率2.68，总市值51.07亿元。 资金流向方面，4月16日，康泰医学主力资金净流出396.30万元，近5日总体呈流入状态，5日共流入 131.70万元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)5康泰医学-262.5830.812.6851.07亿行业平均 45.9448.384.71101.41亿行业中值29.6428.792.3545.52亿1天益医疗-2672.56-2672.561.6719.88亿2硕世生 物-1835.15-1835.151.1537.91亿3诺唯赞-549.11-549.112.5299.35亿4博晖创新-335.30-206.443.6951.46亿6华 大基因-197.28215.792.04200.47亿7奥精医疗-108.26-108.261.3819.61亿8睿昂基因-79.59-79.591.2411.51亿 9热景生物-60.65-60.653.33108.69亿10华大智造-52.74-52.743.96315.97亿11中红医疗-48.32-32.870.7743.02 亿 康泰医 ...